drug

GSK1034702

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by GlaxoSmithKline
2 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

2
Brain Uptake of GSK1034702: a Positron Emission Tomography (PET) Scan Study
NCT00937846Phase 1Completed
Safety, Tolerability and Pharmacokinetics of GSK1034702 in Healthy Subjects
NCT00743405Phase 1Completed

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
GlaxoSmithKline
company
trial
Brain Uptake of GSK1034702: a Positron Emission Tomography (PET) Scan Study
PHASE1
trial
Safety, Tolerability and Pharmacokinetics of GSK1034702 in Healthy Subjects
PHASE1
trial
indication
Schizophrenia
indication
Cognitive Dysfunction
indication
Cognitive Disorders
indication
Alzheimer Disease
indication